Citi upgraded Tandem Diabetes (TNDM) to Neutral from Sell with a price target of $10.35, up from $10. The firm sees a more balanced risk/reward with the shares down 34% since the Q2 report. Citi cites valuation for the upgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Upgraded to Neutral/High Risk Amid Valuation and Acquisition Interest
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
- Tandem Diabetes downgraded to Hold from Buy at Lake Street
- Tandem Diabetes price target lowered to $51 from $53 at Barclays
- Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities